Protalix BioTherapeutics, Inc. (PLX) Net margin 2016–2025
Protalix BioTherapeutics, Inc. (PLX) net profit margin by fiscal year — reported net income divided by reported revenue.
-12.5%FY2025 · since FY2016: -319.2% → -12.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -12.5% | -18.0 pp |
| FY2024 | 5.5% | -7.2 pp |
| FY2023 | 12.7% | +44.0 pp |
| FY2022 | -31.3% | +40.6 pp |
| FY2021 | -71.9% | -61.6 pp |
| FY2020 | -10.4% | +23.0 pp |
| FY2019 | -33.4% | +43.9 pp |
| FY2018 | -77.3% | +318.6 pp |
| FY2017 | -395.9% | -76.6 pp |
| FY2016 | -319.2% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice